ANVS Annovis Bio | $10.96
+4.7% | 7/2/2024 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $67.00 -> $67.00 | Low | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 7/2/2024 |
CGTX Cognition Therapeutics | $2.37
+12.9% | 7/2/2024 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $14.00 -> $14.00 | Low | View details for Rodman & Renshaw rating of Cognition Therapeutics (NASDAQ:CGTX) on 7/2/2024 |
NKTR Nektar Therapeutics | $1.38
+0.7% | 6/28/2024 | Initiated by | Rodman & Renshaw | - | Buy | $2.00 | Low | View details for Rodman & Renshaw rating of Nektar Therapeutics (NASDAQ:NKTR) on 6/28/2024 |
LPTX Leap Therapeutics | $2.20
+1.4% | 6/28/2024 | Initiated by | Rodman & Renshaw | - | Buy | $8.00 | Low | View details for Rodman & Renshaw rating of Leap Therapeutics (NASDAQ:LPTX) on 6/28/2024 |
MURA Mural Oncology | $3.50
+1.2% | 6/28/2024 | Initiated by | Rodman & Renshaw | - | Buy | $15.00 | Low | View details for Rodman & Renshaw rating of Mural Oncology (NASDAQ:MURA) on 6/28/2024 |
SANA Sana Biotechnology | $6.40
+5.8% | 6/26/2024 | Initiated by | Rodman & Renshaw | - | Buy | $16.00 | Low | View details for Rodman & Renshaw rating of Sana Biotechnology (NASDAQ:SANA) on 6/26/2024 |
|
ANRO Alto Neuroscience | $14.36
-0.9% | 6/21/2024 | Initiated by | Rodman & Renshaw | - | Buy | $43.00 | Low | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 6/21/2024 |
COYA Coya Therapeutics | $7.35
-0.1% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $18.00 | Low | View details for Rodman & Renshaw rating of Coya Therapeutics (NASDAQ:COYA) on 6/13/2024 |
TRVI Trevi Therapeutics | $3.25
+2.5% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $7.00 | Low | View details for Rodman & Renshaw rating of Trevi Therapeutics (NASDAQ:TRVI) on 6/13/2024 |
SCLX Scilex | $1.68
-1.2% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $13.00 | Low | View details for Rodman & Renshaw rating of Scilex (NASDAQ:SCLX) on 6/13/2024 |
RANI Rani Therapeutics | $2.93
+2.1% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $10.00 | Low | View details for Rodman & Renshaw rating of Rani Therapeutics (NASDAQ:RANI) on 6/13/2024 |
MNKD MannKind | $5.85
+0.9% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $8.00 | Low | View details for Rodman & Renshaw rating of MannKind (NASDAQ:MNKD) on 6/13/2024 |
HRTX Heron Therapeutics | $3.05
-1.6% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $7.00 | Low | View details for Rodman & Renshaw rating of Heron Therapeutics (NASDAQ:HRTX) on 6/13/2024 |
AVDL Avadel Pharmaceuticals | $16.72
+2.6% | 6/12/2024 | Initiated by | Rodman & Renshaw | - | Buy | $27.00 | Low | View details for Rodman & Renshaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 6/12/2024 |
ANVS Annovis Bio | $10.96
+4.7% | 6/4/2024 | Initiated by | Rodman & Renshaw | - | Buy | $67.00 | Low | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 6/4/2024 |
BHC Bausch Health Companies | $5.99
+1.9% | 8/10/2017 | Reiterated by | Rodman & Renshaw | - | Neutral | $17.00 | High | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 8/10/2017 |
CRMD CorMedix | $4.54
-3.6% | 8/10/2017 | Target Lowered by | Rodman & Renshaw | - | Buy -> Buy | $25.00 -> $15.00 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/10/2017 |
GEVO Gevo | $0.61
| 8/9/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $240.00 | Medium | View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/9/2017 |
POETF POET Technologies | $2.77
+2.6% | 8/7/2017 | Initiated by | Rodman & Renshaw | - | Buy | | High | View details for Rodman & Renshaw rating of POET Technologies (OTCMKTS:POETF) on 8/7/2017 |
VERU Veru | $0.95
| 7/26/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $5.00 | High | View details for Rodman & Renshaw rating of Veru (NASDAQ:VERU) on 7/26/2017 |
PLUG Plug Power | $2.49
+6.9% | 7/24/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $4.00 | Low | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 7/24/2017 |
CAPR Capricor Therapeutics | $4.37
-1.4% | 7/22/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $2.15 | N/A | View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 7/22/2017 |
BYSI BeyondSpring | $1.97
-4.8% | 7/14/2017 | Target Raised by | Rodman & Renshaw | - | Buy -> Buy | $43.00 -> $50.00 | Medium | View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 7/14/2017 |
FBIO Fortress Biotech | $2.25
-13.5% | 7/11/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $165.00 | Low | View details for Rodman & Renshaw rating of Fortress Biotech (NASDAQ:FBIO) on 7/11/2017 |
AQMS Aqua Metals | $0.32
| 7/2/2017 | Initiated by | Rodman & Renshaw | - | Buy | $25.00 -> $25.00 | Low | View details for Rodman & Renshaw rating of Aqua Metals (NASDAQ:AQMS) on 7/2/2017 |
EMAN eMagin | $2.07
| 6/23/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $4.00 | N/A | View details for Rodman & Renshaw rating of eMagin (NYSEAMERICAN:EMAN) on 6/23/2017 |
AQMS Aqua Metals | $0.32
| 6/22/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $25.00 | Low | View details for Rodman & Renshaw rating of Aqua Metals (NASDAQ:AQMS) on 6/22/2017 |
USA Americas Silver | C$0.34
| 6/15/2017 | Initiated by | Rodman & Renshaw | - | Buy | C$4.00 | N/A | View details for Rodman & Renshaw rating of Americas Silver (TSE:USA) on 6/15/2017 |
USAS Americas Silver | $0.24
| 6/15/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $4.00 -> $4.00 | Medium | View details for Rodman & Renshaw rating of Americas Silver (NYSEAMERICAN:USAS) on 6/15/2017 |
APTO Aptose Biosciences | $0.57
| 6/8/2017 | Initiated by | Rodman & Renshaw | - | Neutral -> Neutral | | High | View details for Rodman & Renshaw rating of Aptose Biosciences (NASDAQ:APTO) on 6/8/2017 |
EYPT EyePoint Pharmaceuticals | $9.71
+2.6% | 5/30/2017 | Initiated by | Rodman & Renshaw | - | Buy | $800.00 | High | View details for Rodman & Renshaw rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 5/30/2017 |
PIRS Pieris Pharmaceuticals | $17.01
-1.7% | 5/30/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $720.00 | High | View details for Rodman & Renshaw rating of Pieris Pharmaceuticals (NASDAQ:PIRS) on 5/30/2017 |
PLX Protalix BioTherapeutics | $1.15
| 5/23/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $50.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 5/23/2017 |
ACAD ACADIA Pharmaceuticals | $19.14
+3.2% | 5/22/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $60.00 | Low | View details for Rodman & Renshaw rating of ACADIA Pharmaceuticals (NASDAQ:ACAD) on 5/22/2017 |
BHC Bausch Health Companies | $5.99
+1.9% | 5/19/2017 | Reiterated by | Rodman & Renshaw | - | Neutral | $17.00 | Medium | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 5/19/2017 |
MGIC Magic Software Enterprises | $11.68
-0.3% | 5/17/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $9.00 -> $10.00 | Medium | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 5/17/2017 |
SSKN STRATA Skin Sciences | $3.34
+1.2% | 5/16/2017 | Target Raised by | Rodman & Renshaw | - | Buy -> Buy | $15.00 -> $120.00 | High | View details for Rodman & Renshaw rating of STRATA Skin Sciences (NASDAQ:SSKN) on 5/16/2017 |
IOVA Iovance Biotherapeutics | $9.25
-1.9% | 5/10/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $13.00 | Low | View details for Rodman & Renshaw rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/10/2017 |
CRMD CorMedix | $4.54
-3.6% | 5/5/2017 | Target Lowered by | Rodman & Renshaw | - | Buy | $30.00 -> $25.00 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 5/5/2017 |
AMSC American Superconductor | $25.44
+1.6% | 4/28/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $10.00 -> $7.50 | High | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 4/28/2017 |
Man Who Called Nvidia at $1.10 Says Buy This Now... (Ad) In 2004, one man called Nvidia before just about anyone knew it existed.
Now, this same guy says a new company could become the next to soar like Nvidia. Watch Alex's "Next Magnificent Seven" presentation now. |
ALIM Alimera Sciences | $5.57
-0.4% | 4/27/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $60.00 | High | View details for Rodman & Renshaw rating of Alimera Sciences (NASDAQ:ALIM) on 4/27/2017 |
GOLD Barrick Gold | $17.78
+0.3% | 4/24/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $4.25 -> $4.50 | N/A | View details for Rodman & Renshaw rating of Barrick Gold (NYSE:GOLD) on 4/24/2017 |
PLX Protalix BioTherapeutics | $1.15
| 4/17/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $40.00 -> $50.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/17/2017 |
PLX Protalix BioTherapeutics | $1.15
| 4/17/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $40.00 -> $50.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/17/2017 |
WRN Western Copper and Gold | C$1.56
+4.0% | 4/10/2017 | Reiterated by | Rodman & Renshaw | - | Buy | C$2.00 | N/A | View details for Rodman & Renshaw rating of Western Copper and Gold (TSE:WRN) on 4/10/2017 |
WRN Western Copper and Gold | $1.12
+2.8% | 4/7/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $2.00 | Medium | View details for Rodman & Renshaw rating of Western Copper and Gold (NYSEAMERICAN:WRN) on 4/7/2017 |
PLUG Plug Power | $2.49
+6.9% | 4/6/2017 | Target Raised by | Rodman & Renshaw | - | Buy -> Buy | $3.00 -> $4.00 | High | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 4/6/2017 |
BYSI BeyondSpring | $1.97
-4.8% | 4/4/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $43.00 | Low | View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 4/4/2017 |
CYTK Cytokinetics | $59.69
+2.0% | 3/23/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $25.00 | Medium | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 3/23/2017 |
HROW Harrow | $24.44
+0.9% | 3/22/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $5.00 | High | View details for Rodman & Renshaw rating of Harrow (NASDAQ:HROW) on 3/22/2017 |
MAG MAG Silver | $13.09
+1.1% | 3/9/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $20.00 -> $20.50 | Low | View details for Rodman & Renshaw rating of MAG Silver (NYSEAMERICAN:MAG) on 3/9/2017 |
CYTK Cytokinetics | $59.69
+2.0% | 3/8/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $25.00 | High | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 3/8/2017 |
BHC Bausch Health Companies | $5.99
+1.9% | 3/6/2017 | Target Lowered by | Rodman & Renshaw | - | Neutral | $23.00 -> $17.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 3/6/2017 |
MGIC Magic Software Enterprises | $11.68
-0.3% | 3/6/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $8.00 -> $9.00 | N/A | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 3/6/2017 |
QRHC Quest Resource | $8.79
+1.2% | 3/6/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $5.00 | N/A | View details for Rodman & Renshaw rating of Quest Resource (NASDAQ:QRHC) on 3/6/2017 |
BHC Bausch Health Companies | $5.99
+1.9% | 2/27/2017 | Reiterated by | Rodman & Renshaw | - | Neutral | $23.00 -> $17.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 2/27/2017 |
SSKN STRATA Skin Sciences | $3.34
+1.2% | 2/21/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $15.00 | N/A | View details for Rodman & Renshaw rating of STRATA Skin Sciences (NASDAQ:SSKN) on 2/21/2017 |
CAPR Capricor Therapeutics | $4.37
-1.4% | 2/13/2017 | Initiated by | Rodman & Renshaw | - | Buy | $14.00 | N/A | View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 2/13/2017 |
BLRX BioLineRx | $0.84
-3.4% | 2/13/2017 | Initiated by | Rodman & Renshaw | - | Buy | $3.00 | N/A | View details for Rodman & Renshaw rating of BioLineRx (NASDAQ:BLRX) on 2/13/2017 |
ABEO Abeona Therapeutics | $5.10
+1.4% | 2/7/2017 | Reiterated by | Rodman & Renshaw | Analyst ram selvaraju | Buy | $425.00 -> $500.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 2/7/2017 |
BHC Bausch Health Companies | $5.99
+1.9% | 1/31/2017 | Downgraded by | Rodman & Renshaw | - | Buy -> Neutral | | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 1/31/2017 |
ASM Avino Silver & Gold Mines | $1.03
+2.0% | 1/24/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $3.50 -> $4.00 | N/A | View details for Rodman & Renshaw rating of Avino Silver & Gold Mines (NYSE:ASM) on 1/24/2017 |
ASM Avino Silver & Gold Mines | $1.04
+2.0% | 1/24/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $3.50 -> $4.00 | N/A | View details for Rodman & Renshaw rating of Avino Silver & Gold Mines (NYSE:ASM) on 1/24/2017 |
CHEK Check-Cap | $2.01
-0.5% | 1/19/2017 | Initiated by | Rodman & Renshaw | - | Buy | $1,440.00 | N/A | View details for Rodman & Renshaw rating of Check-Cap (NASDAQ:CHEK) on 1/19/2017 |
CDXC ChromaDex | $3.07
-3.8% | 1/3/2017 | Initiated by | Rodman & Renshaw | - | Buy | $6.00 | N/A | View details for Rodman & Renshaw rating of ChromaDex (NASDAQ:CDXC) on 1/3/2017 |
PLUG Plug Power | $2.49
+6.9% | 12/6/2016 | Initiated by | Rodman & Renshaw | - | Buy | $3.00 | N/A | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 12/6/2016 |
GOLD Barrick Gold | $17.78
+0.3% | 11/28/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $4.00 -> $4.25 | N/A | View details for Rodman & Renshaw rating of Barrick Gold (NYSE:GOLD) on 11/28/2016 |
HROW Harrow | $24.44
+0.9% | 11/28/2016 | Initiated by | Rodman & Renshaw | - | Buy | $5.00 | N/A | View details for Rodman & Renshaw rating of Harrow (NASDAQ:HROW) on 11/28/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 11/10/2016 | Downgraded by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy -> Neutral | $81.00 -> $23.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 11/10/2016 |
GGD GoGold Resources | C$1.39
| 10/7/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | C$3.50 -> C$3.00 | N/A | View details for Rodman & Renshaw rating of GoGold Resources (TSE:GGD) on 10/7/2016 |
CYDY CytoDyn | $0.14
| 10/6/2016 | Initiated by | Rodman & Renshaw | - | Buy | $1.60 | N/A | View details for Rodman & Renshaw rating of CytoDyn (OTCMKTS:CYDY) on 10/6/2016 |
DRRX DURECT | $1.67
+1.2% | 9/27/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 -> $35.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 9/27/2016 |
AYTU Aytu BioPharma | $2.72
+0.7% | 9/26/2016 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | N/A | View details for Rodman & Renshaw rating of Aytu BioPharma (NASDAQ:AYTU) on 9/26/2016 |
CLNE Clean Energy Fuels | $2.61
-3.7% | 9/23/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $5.00 -> $6.30 | N/A | View details for Rodman & Renshaw rating of Clean Energy Fuels (NASDAQ:CLNE) on 9/23/2016 |
UUUU Energy Fuels | $5.67
+1.3% | 9/22/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $5.00 -> $6.30 | N/A | View details for Rodman & Renshaw rating of Energy Fuels (NYSE:UUUU) on 9/22/2016 |
UUUU Energy Fuels | $5.67
+1.3% | 9/22/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $6.30 -> $5.00 | N/A | View details for Rodman & Renshaw rating of Energy Fuels (NYSE:UUUU) on 9/22/2016 |
VNRX VolitionRx | $0.76
+10.2% | 9/7/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $12.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 9/7/2016 |
VNRX VolitionRx | $0.76
+10.2% | 9/7/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $12.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 9/7/2016 |
MEEC Midwest Energy Emissions | $0.74
+5.7% | 9/7/2016 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Midwest Energy Emissions (OTCMKTS:MEEC) on 9/7/2016 |
HL Hecla Mining | $5.66
-1.4% | 9/6/2016 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | N/A | View details for Rodman & Renshaw rating of Hecla Mining (NYSE:HL) on 9/6/2016 |
CANF Can-Fite BioPharma | $3.71
+5.4% | 8/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $60.00 | N/A | View details for Rodman & Renshaw rating of Can-Fite BioPharma (NYSE:CANF) on 8/29/2016 |
REI Ring Energy | $1.93
-1.0% | 8/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $15.00 | N/A | View details for Rodman & Renshaw rating of Ring Energy (NYSEAMERICAN:REI) on 8/29/2016 |
DRIO DarioHealth | $1.21
+3.4% | 8/22/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 8/22/2016 |
ORMP Oramed Pharmaceuticals | $2.60
+2.4% | 8/21/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 8/21/2016 |
ABEO Abeona Therapeutics | $5.10
+1.4% | 8/21/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 8/21/2016 |
SMT Sierra Metals | C$0.75
+1.4% | 8/18/2016 | Reiterated by | Rodman & Renshaw | - | Buy | C$3.00 | N/A | View details for Rodman & Renshaw rating of Sierra Metals (TSE:SMT) on 8/18/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 8/9/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 -> $81.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 8/9/2016 |
ABEO Abeona Therapeutics | $5.10
+1.4% | 8/5/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 8/5/2016 |
DRRX DURECT | $1.67
+1.2% | 8/3/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 8/3/2016 |
EKSO Ekso Bionics | $1.30
-2.3% | 7/31/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ekso Bionics (NASDAQ:EKSO) on 7/31/2016 |
Nvidia’s Quiet $1 Trillion Pivot (Ad) Nvidia recently added $277 billion in market cap …
IN ONE DAY. Find out details on these three critical Nvidia partners immediately. |
BHC Bausch Health Companies | $5.99
+1.9% | 7/28/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 7/28/2016 |
KTRA Kintara Therapeutics | $0.24
+14.0% | 7/18/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Kintara Therapeutics (NASDAQ:KTRA) on 7/18/2016 |
F Ford Motor | $11.19
+0.3% | 7/18/2016 | Initiated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ford Motor (NYSE:F) on 7/18/2016 |
OESX Orion Energy Systems | $1.07
+3.9% | 7/18/2016 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Orion Energy Systems (NASDAQ:OESX) on 7/18/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 7/17/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 7/17/2016 |
PLX Protalix BioTherapeutics | $1.15
| 7/11/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 7/11/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 7/6/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 7/6/2016 |
DRRX DURECT | $1.67
+1.2% | 7/6/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 7/6/2016 |
INO Inovio Pharmaceuticals | $11.32
+3.4% | 6/21/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $2,448.00 | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 6/21/2016 |
WPRT Westport Fuel Systems | $6.03
+1.3% | 6/20/2016 | Initiated by | Rodman & Renshaw | - | Buy | $50.00 | N/A | View details for Rodman & Renshaw rating of Westport Fuel Systems (NASDAQ:WPRT) on 6/20/2016 |
VNRX VolitionRx | $0.76
+10.2% | 6/16/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 6/16/2016 |
KTRA Kintara Therapeutics | $0.24
+14.0% | 5/24/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Kintara Therapeutics (NASDAQ:KTRA) on 5/24/2016 |
DRIO DarioHealth | $1.21
+3.4% | 5/24/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 5/24/2016 |
ABEO Abeona Therapeutics | $5.10
+1.4% | 5/18/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 5/18/2016 |
VNRX VolitionRx | $0.76
+10.2% | 5/16/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 5/16/2016 |
DRRX DURECT | $1.67
+1.2% | 5/13/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 5/13/2016 |
ORMP Oramed Pharmaceuticals | $2.60
+2.4% | 5/13/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 5/13/2016 |
MBOT Microbot Medical | $1.04
+5.1% | 5/10/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Microbot Medical (NASDAQ:MBOT) on 5/10/2016 |
DRIO DarioHealth | $1.21
+3.4% | 5/9/2016 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 5/9/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 5/3/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $105.00 -> $102.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 5/3/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 4/26/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $105.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 4/26/2016 |
DRRX DURECT | $1.67
+1.2% | 4/25/2016 | Initiated by | Rodman & Renshaw | - | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 4/25/2016 |
VNRX VolitionRx | $0.76
+10.2% | 4/21/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 4/21/2016 |
ABEO Abeona Therapeutics | $5.10
+1.4% | 4/20/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 4/20/2016 |
MBOT Microbot Medical | $1.04
+5.1% | 4/20/2016 | Initiated by | Rodman & Renshaw | - | Buy | $18.00 | N/A | View details for Rodman & Renshaw rating of Microbot Medical (NASDAQ:MBOT) on 4/20/2016 |
AG First Majestic Silver | $5.85
| 4/15/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $6.00 -> $8.75 | N/A | View details for Rodman & Renshaw rating of First Majestic Silver (NYSE:AG) on 4/15/2016 |
SMLR Semler Scientific | $33.38
+3.9% | 4/15/2016 | Initiated by | Rodman & Renshaw | - | Buy | $8.00 | N/A | View details for Rodman & Renshaw rating of Semler Scientific (NASDAQ:SMLR) on 4/15/2016 |
EXK Endeavour Silver | $4.32
-0.7% | 4/12/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $2.50 -> $3.40 | N/A | View details for Rodman & Renshaw rating of Endeavour Silver (NYSE:EXK) on 4/12/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 4/11/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $118.00 -> $105.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 4/11/2016 |
INO Inovio Pharmaceuticals | $11.32
+3.4% | 4/9/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 4/9/2016 |
VNRX VolitionRx | $0.76
+10.2% | 4/9/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 4/9/2016 |
EKSO Ekso Bionics | $1.30
-2.3% | 4/5/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $21.00 | N/A | View details for Rodman & Renshaw rating of Ekso Bionics (NASDAQ:EKSO) on 4/5/2016 |
KTRA Kintara Therapeutics | $0.24
+14.0% | 4/4/2016 | Initiated by | Rodman & Renshaw | - | Buy | $1,500.00 | N/A | View details for Rodman & Renshaw rating of Kintara Therapeutics (NASDAQ:KTRA) on 4/4/2016 |
PLX Protalix BioTherapeutics | $1.15
| 4/4/2016 | Initiated by | Rodman & Renshaw | - | Buy | $35.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/4/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 4/3/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 4/3/2016 |
AMSC American Superconductor | $25.44
+1.6% | 4/1/2016 | Reiterated by | Rodman & Renshaw | Analyst Amit Dayal | Neutral | | N/A | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 4/1/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 3/28/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $118.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 3/28/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 3/22/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 3/22/2016 |
NNDM Nano Dimension | $2.46
+7.4% | 3/21/2016 | Initiated by | Rodman & Renshaw | - | Buy | $700.00 | N/A | View details for Rodman & Renshaw rating of Nano Dimension (NASDAQ:NNDM) on 3/21/2016 |
INO Inovio Pharmaceuticals | $11.32
+3.4% | 3/20/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 3/20/2016 |
UUUU Energy Fuels | $5.67
+1.3% | 3/17/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $6.90 -> $6.30 | N/A | View details for Rodman & Renshaw rating of Energy Fuels (NYSE:UUUU) on 3/17/2016 |
CRMD CorMedix | $4.54
-3.6% | 3/17/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $32.50 -> $37.50 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 3/17/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 3/16/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $150.00 -> $118.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 3/16/2016 |
MUX McEwen Mining | $9.12
-0.8% | 3/14/2016 | Target Raised by | Rodman & Renshaw | - | | $13.00 -> $24.00 | N/A | View details for Rodman & Renshaw rating of McEwen Mining (NYSE:MUX) on 3/14/2016 |
VNRX VolitionRx | $0.76
+10.2% | 3/14/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 3/14/2016 |
INSG Inseego | $9.75
-1.6% | 3/7/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $60.00 -> $30.00 | N/A | View details for Rodman & Renshaw rating of Inseego (NASDAQ:INSG) on 3/7/2016 |
PLM PolyMet Mining | $2.10
-0.5% | 3/4/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $2.00 -> $2.40 | N/A | View details for Rodman & Renshaw rating of PolyMet Mining (NYSEAMERICAN:PLM) on 3/4/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 3/2/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 3/2/2016 |
AG First Majestic Silver | $5.85
| 2/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $6.00 | N/A | View details for Rodman & Renshaw rating of First Majestic Silver (NYSE:AG) on 2/29/2016 |
EXK Endeavour Silver | $4.32
-0.7% | 2/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Endeavour Silver (NYSE:EXK) on 2/29/2016 |
Get out of cash before the Fed's next meeting (Ad) "How I 6X-ed my wife's 401K in 1 year"
At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains." Click here now to watch this exclusive interview |
BHC Bausch Health Companies | $5.99
+1.9% | 2/23/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $150.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 2/23/2016 |
RDCM RADCOM | $10.15
+0.9% | 2/18/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $12.00 -> $16.00 | N/A | View details for Rodman & Renshaw rating of RADCOM (NASDAQ:RDCM) on 2/18/2016 |
BHC Bausch Health Companies | $5.99
+1.9% | 2/16/2016 | Initiated by | Rodman & Renshaw | - | Buy | $150.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 2/16/2016 |
TMQ Trilogy Metals | $0.68
| 2/11/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $1.40 -> $1.30 | N/A | View details for Rodman & Renshaw rating of Trilogy Metals (NYSEAMERICAN:TMQ) on 2/11/2016 |
TMQ Trilogy Metals | $0.68
| 2/10/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $1.40 -> $1.30 | N/A | View details for Rodman & Renshaw rating of Trilogy Metals (NYSEAMERICAN:TMQ) on 2/10/2016 |
BCRX BioCryst Pharmaceuticals | $7.85
+4.0% | 2/9/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $24.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) on 2/9/2016 |
VNRX VolitionRx | $0.76
+10.2% | 2/1/2016 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 2/1/2016 |
INO Inovio Pharmaceuticals | $11.32
+3.4% | 1/29/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 1/29/2016 |
IPWR Ideal Power | $7.35
+3.1% | 1/26/2016 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of Ideal Power (NASDAQ:IPWR) on 1/26/2016 |
AMSC American Superconductor | $25.44
+1.6% | 1/13/2016 | Initiated by | Rodman & Renshaw | - | Buy | $10.00 | N/A | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 1/13/2016 |
ORMP Oramed Pharmaceuticals | $2.60
+2.4% | 1/10/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 1/10/2016 |
GGD GoGold Resources | C$1.39
| 12/21/2015 | Target Raised by | Rodman & Renshaw | - | | C$2.70 -> C$2.90 | N/A | View details for Rodman & Renshaw rating of GoGold Resources (TSE:GGD) on 12/21/2015 |
MVIS MicroVision | $1.12
-3.4% | 12/17/2015 | Initiated by | Rodman & Renshaw | - | Buy | $3.50 | N/A | View details for Rodman & Renshaw rating of MicroVision (NASDAQ:MVIS) on 12/17/2015 |
CRMD CorMedix | $4.54
-3.6% | 12/16/2015 | Initiated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 12/16/2015 |
VUZI Vuzix | $1.30
+4.8% | 12/10/2015 | Initiated by | Rodman & Renshaw | - | Buy | $10.00 | N/A | View details for Rodman & Renshaw rating of Vuzix (NASDAQ:VUZI) on 12/10/2015 |
CRMD CorMedix | $4.54
-3.6% | 11/12/2015 | Initiated by | Rodman & Renshaw | - | Buy | $32.50 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 11/12/2015 |
BLDP Ballard Power Systems | $2.30
+2.2% | 10/5/2015 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 10/5/2015 |
ORMP Oramed Pharmaceuticals | $2.60
+2.4% | 10/1/2015 | Initiated by | Rodman & Renshaw | - | Buy | $24.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 10/1/2015 |
BLDP Ballard Power Systems | $2.30
+2.2% | 8/20/2015 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 8/20/2015 |
GEVO Gevo | $0.61
| 8/19/2015 | Initiated by | Rodman & Renshaw | - | Buy | $100.00 | N/A | View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/19/2015 |
BLDP Ballard Power Systems | $2.30
+2.2% | 7/14/2015 | Initiated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 7/14/2015 |
CPRX Catalyst Pharmaceuticals | $17.59
+1.3% | 8/27/2012 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | $3.70 | N/A | View details for Rodman & Renshaw rating of Catalyst Pharmaceuticals (NASDAQ:CPRX) on 8/27/2012 |
CYTK Cytokinetics | $59.69
+2.0% | 7/31/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $2.00 | N/A | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 7/31/2012 |
ALNY Alnylam Pharmaceuticals | $234.84
-1.3% | 7/31/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $22.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 7/31/2012 |
BMY Bristol-Myers Squibb | $50.40
+11.3% | 7/27/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $38.00 -> $39.50 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 7/27/2012 |
AMGN Amgen | $334.85
+0.2% | 7/23/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $73.00 -> $89.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 7/23/2012 |
ALNY Alnylam Pharmaceuticals | $234.84
-1.3% | 7/16/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 7/16/2012 |
ALGT Allegiant Travel | $52.91
+3.7% | 7/13/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $72.00 -> $79.00 | N/A | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 7/13/2012 |
BMY Bristol-Myers Squibb | $50.40
+11.3% | 7/5/2012 | Reiterated by | Rodman & Renshaw | - | Market Perform | $38.00 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 7/5/2012 |
ASMB Assembly Biosciences | $14.94
+0.7% | 6/26/2012 | Target Lowered by | Rodman & Renshaw | - | | $132.00 | N/A | View details for Rodman & Renshaw rating of Assembly Biosciences (NASDAQ:ASMB) on 6/26/2012 |
RPMT Rego Payment Architectures | $1.00
+5.3% | 6/25/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $5.00 | N/A | View details for Rodman & Renshaw rating of Rego Payment Architectures (OTCMKTS:RPMT) on 6/25/2012 |
AMGN Amgen | $334.85
+0.2% | 6/21/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $57.00 -> $73.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 6/21/2012 |
MNOV MediciNova | $1.31
+0.8% | 6/19/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of MediciNova (NASDAQ:MNOV) on 6/19/2012 |
DCO Ducommun | $64.19
+2.1% | 5/24/2012 | Initiated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Ducommun (NYSE:DCO) on 5/24/2012 |
POWL Powell Industries | $139.28
+4.1% | 5/10/2012 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | $43.00 | N/A | View details for Rodman & Renshaw rating of Powell Industries (NASDAQ:POWL) on 5/10/2012 |
NPO Enpro | $171.51
+2.6% | 5/4/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $47.00 -> $50.00 | N/A | View details for Rodman & Renshaw rating of Enpro (NYSE:NPO) on 5/4/2012 |
RMTI Rockwell Medical | $1.89
+2.2% | 4/24/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $176.00 | N/A | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 4/24/2012 |
SYK Stryker | $331.67
+1.3% | 4/20/2012 | Downgraded by | Rodman & Renshaw | - | Outperform -> Market Perform | | N/A | View details for Rodman & Renshaw rating of Stryker (NYSE:SYK) on 4/20/2012 |
PODD Insulet | $193.30
+1.3% | 4/18/2012 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | | N/A | View details for Rodman & Renshaw rating of Insulet (NASDAQ:PODD) on 4/18/2012 |
B Barnes Group | $41.10
-2.4% | 4/3/2012 | Initiated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Barnes Group (NYSE:B) on 4/3/2012 |
TRS TriMas | $27.51
+1.7% | 3/15/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $32.00 | N/A | View details for Rodman & Renshaw rating of TriMas (NASDAQ:TRS) on 3/15/2012 |
OMER Omeros | $5.22
-1.1% | 3/13/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $13.00 -> $16.00 | N/A | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 3/13/2012 |
AMGN Amgen | $334.85
+0.2% | 3/7/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $57.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 3/7/2012 |
VSTM Verastem | $2.96
-0.3% | 3/7/2012 | Initiated by | Rodman & Renshaw | - | Buy -> Market Perform | | N/A | View details for Rodman & Renshaw rating of Verastem (NASDAQ:VSTM) on 3/7/2012 |
ANIP ANI Pharmaceuticals | $63.25
+2.0% | 2/27/2012 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 2/27/2012 |
MNTX Manitex International | $5.08
+4.5% | 2/23/2012 | Target Raised by | Rodman & Renshaw | - | | $10.00 | N/A | View details for Rodman & Renshaw rating of Manitex International (NASDAQ:MNTX) on 2/23/2012 |
MDGL Madrigal Pharmaceuticals | $284.49
+0.4% | 2/22/2012 | Reiterated by | Rodman & Renshaw | - | Market Perform | $8.00 | N/A | View details for Rodman & Renshaw rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 2/22/2012 |
MGIC Magic Software Enterprises | $11.68
-0.3% | 2/15/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $8.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 2/15/2012 |
ALNY Alnylam Pharmaceuticals | $234.84
-1.3% | 2/6/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $19.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/6/2012 |
DAL Delta Air Lines | $44.13
+1.5% | 2/6/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $14.00 | N/A | View details for Rodman & Renshaw rating of Delta Air Lines (NYSE:DAL) on 2/6/2012 |
Get out of cash before the Fed's next meeting (Ad) "How I 6X-ed my wife's 401K in 1 year"
At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains." Click here now to watch this exclusive interview |
ALGT Allegiant Travel | $52.91
+3.7% | 2/2/2012 | Target Raised by | Rodman & Renshaw | - | | $62.00 | N/A | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 2/2/2012 |
POWL Powell Industries | $139.28
+4.1% | 1/26/2012 | Initiated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Powell Industries (NASDAQ:POWL) on 1/26/2012 |
SILC Silicom | $16.10
+1.0% | 1/24/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $20.00 -> $25.00 | N/A | View details for Rodman & Renshaw rating of Silicom (NASDAQ:SILC) on 1/24/2012 |
BMY Bristol-Myers Squibb | $50.40
+11.3% | 1/23/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $51.00 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 1/23/2012 |
LUV Southwest Airlines | $27.23
-3.0% | 1/20/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 1/20/2012 |
AMGN Amgen | $334.85
+0.2% | 1/17/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $57.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 1/17/2012 |
COOL Corner Growth Acquisition | $11.10
| 1/5/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $7.00 | N/A | View details for Rodman & Renshaw rating of Corner Growth Acquisition (NASDAQ:COOL) on 1/5/2012 |
MDGL Madrigal Pharmaceuticals | $284.49
+0.4% | 1/5/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $8.00 | N/A | View details for Rodman & Renshaw rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 1/5/2012 |
ALNY Alnylam Pharmaceuticals | $234.84
-1.3% | 1/4/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 1/4/2012 |
WWD Woodward | $183.13
+2.1% | 1/4/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $52.00 | N/A | View details for Rodman & Renshaw rating of Woodward (NASDAQ:WWD) on 1/4/2012 |
AMGN Amgen | $334.85
+0.2% | 12/23/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $57.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 12/23/2011 |
ANIP ANI Pharmaceuticals | $63.25
+2.0% | 12/15/2011 | Downgraded by | Rodman & Renshaw | - | Outperform -> Market Perform | | N/A | View details for Rodman & Renshaw rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/15/2011 |
INTC Intel | $31.35
+0.8% | 12/13/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $27.00 | N/A | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 12/13/2011 |
BMY Bristol-Myers Squibb | $50.40
+11.3% | 12/13/2011 | Target Lowered by | Rodman & Renshaw | - | | $51.00 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 12/13/2011 |
ALNY Alnylam Pharmaceuticals | $234.84
-1.3% | 12/12/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 12/12/2011 |
BMY Bristol-Myers Squibb | $50.40
+11.3% | 12/12/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $52.50 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 12/12/2011 |
OMER Omeros | $5.22
-1.1% | 12/5/2011 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | $13.00 | N/A | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 12/5/2011 |
ROG Rogers | $123.17
+0.4% | 12/2/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $55.00 | N/A | View details for Rodman & Renshaw rating of Rogers (NYSE:ROG) on 12/2/2011 |
ALNY Alnylam Pharmaceuticals | $234.84
-1.3% | 12/1/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 12/1/2011 |
AMGN Amgen | $334.85
+0.2% | 12/1/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $62.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 12/1/2011 |
CRIS Curis | $6.12
+1.7% | 11/30/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $600.00 | N/A | View details for Rodman & Renshaw rating of Curis (NASDAQ:CRIS) on 11/30/2011 |
EW Edwards Lifesciences | $62.37
+4.5% | 11/29/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 11/29/2011 |
AAPL Apple | $217.96
+0.2% | 11/29/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $16.07 | N/A | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 11/29/2011 |
LUV Southwest Airlines | $27.23
-3.0% | 11/21/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 11/21/2011 |
DELL Dell Technologies | $113.59
+1.9% | 11/15/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $18.00 | N/A | View details for Rodman & Renshaw rating of Dell Technologies (NYSE:DELL) on 11/15/2011 |
MNTX Manitex International | $5.08
+4.5% | 11/15/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $6.50 | N/A | View details for Rodman & Renshaw rating of Manitex International (NASDAQ:MNTX) on 11/15/2011 |
ALIM Alimera Sciences | $5.57
-0.4% | 11/14/2011 | Downgraded by | Rodman & Renshaw | - | Outperform -> Market Perform | | N/A | View details for Rodman & Renshaw rating of Alimera Sciences (NASDAQ:ALIM) on 11/14/2011 |
EW Edwards Lifesciences | $62.37
+4.5% | 11/11/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 11/11/2011 |
ADNT Adient | $25.07
-0.1% | 11/11/2011 | Initiated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Adient (NYSE:ADNT) on 11/11/2011 |
ALNY Alnylam Pharmaceuticals | $234.84
-1.3% | 11/10/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/10/2011 |
INTC Intel | $31.35
+0.8% | 11/10/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 11/10/2011 |
CRIS Curis | $6.12
+1.7% | 11/10/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $600.00 | N/A | View details for Rodman & Renshaw rating of Curis (NASDAQ:CRIS) on 11/10/2011 |
AAPL Apple | $217.96
+0.2% | 11/9/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 11/9/2011 |
GERN Geron | $4.66
+8.6% | 11/9/2011 | Target Lowered by | Rodman & Renshaw | - | | $4.00 | N/A | View details for Rodman & Renshaw rating of Geron (NASDAQ:GERN) on 11/9/2011 |
BMY Bristol-Myers Squibb | $50.40
+11.3% | 11/9/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $52.50 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 11/9/2011 |
USEG U.S. Energy | $1.05
+1.0% | 11/8/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $47.50 | N/A | View details for Rodman & Renshaw rating of U.S. Energy (NASDAQ:USEG) on 11/8/2011 |
ERII Energy Recovery | $14.91
+0.5% | 11/4/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Energy Recovery (NASDAQ:ERII) on 11/4/2011 |
AUDC AudioCodes | $10.90
+0.2% | 11/1/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of AudioCodes (NASDAQ:AUDC) on 11/1/2011 |
CYTK Cytokinetics | $59.69
+2.0% | 11/1/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $4.00 | N/A | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 11/1/2011 |
ALNY Alnylam Pharmaceuticals | $234.84
-1.3% | 11/1/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/1/2011 |
BMY Bristol-Myers Squibb | $50.40
+11.3% | 10/28/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $52.50 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 10/28/2011 |
CEVA CEVA | $20.57
+4.0% | 10/27/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of CEVA (NASDAQ:CEVA) on 10/27/2011 |
ALGT Allegiant Travel | $52.91
+3.7% | 10/27/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 10/27/2011 |
JBLU JetBlue Airways | $6.21
+3.0% | 10/27/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | $6.00 | N/A | View details for Rodman & Renshaw rating of JetBlue Airways (NASDAQ:JBLU) on 10/27/2011 |
DAL Delta Air Lines | $44.13
+1.5% | 10/26/2011 | Target Raised by | Rodman & Renshaw | - | | $14.00 | N/A | View details for Rodman & Renshaw rating of Delta Air Lines (NYSE:DAL) on 10/26/2011 |
LUV Southwest Airlines | $27.23
-3.0% | 10/21/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 10/21/2011 |
ALK Alaska Air Group | $39.45
+2.0% | 10/21/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $39.00 | N/A | View details for Rodman & Renshaw rating of Alaska Air Group (NYSE:ALK) on 10/21/2011 |
INTC Intel | $31.35
+0.8% | 10/19/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $27.00 | N/A | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 10/19/2011 |
AAPL Apple | $217.96
+0.2% | 10/19/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 10/19/2011 |
ENZ Enzo Biochem | $1.15
+0.9% | 10/18/2011 | Target Lowered by | Rodman & Renshaw | - | Outperform | $7.00 -> $5.00 | N/A | View details for Rodman & Renshaw rating of Enzo Biochem (NYSE:ENZ) on 10/18/2011 |
ALNY Alnylam Pharmaceuticals | $234.84
-1.3% | 10/14/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 10/14/2011 |
BMY Bristol-Myers Squibb | $50.40
+11.3% | 10/14/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $52.50 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 10/14/2011 |
NPO Enpro | $171.51
+2.6% | 10/13/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $47.00 | N/A | View details for Rodman & Renshaw rating of Enpro (NYSE:NPO) on 10/13/2011 |
CYTK Cytokinetics | $59.69
+2.0% | 10/13/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $4.00 | N/A | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 10/13/2011 |
CEVA CEVA | $20.57
+4.0% | 10/7/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $36.00 | N/A | View details for Rodman & Renshaw rating of CEVA (NASDAQ:CEVA) on 10/7/2011 |
AAPL Apple | $217.96
+0.2% | 10/5/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $16.07 | N/A | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 10/5/2011 |
INTC Intel | $31.35
+0.8% | 10/3/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 10/3/2011 |
AGEN Agenus | $6.56
+9.9% | 9/26/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $40.00 | N/A | View details for Rodman & Renshaw rating of Agenus (NASDAQ:AGEN) on 9/26/2011 |
CGA China Green Agriculture | $2.16
+1.9% | 9/15/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of China Green Agriculture (NYSE:CGA) on 9/15/2011 |
SEED Origin Agritech | $3.09
| 9/15/2011 | Downgraded by | Rodman & Renshaw | - | Outperform -> Market Perform | | N/A | View details for Rodman & Renshaw rating of Origin Agritech (NASDAQ:SEED) on 9/15/2011 |
